ImmunityBio Inc. (IBRX)
NASDAQ: IBRX
· Real-Time Price · USD
2.58
-0.13 (-4.80%)
At close: Aug 15, 2025, 2:33 PM
-4.80% (1D)
| Bid | 2.57 |
| Market Cap | 2.43B |
| Revenue (ttm) | 56.6M |
| Net Income (ttm) | -367.09M |
| EPS (ttm) | -0.48 |
| PE Ratio (ttm) | -5.36 |
| Forward PE | -7.18 |
| Analyst | Buy |
| Ask | 2.59 |
| Volume | 7,295,207 |
| Avg. Volume (20D) | 9,370,488.5 |
| Open | 2.72 |
| Previous Close | 2.71 |
| Day's Range | 2.56 - 2.72 |
| 52-Week Range | 1.83 - 7.48 |
| Beta | -0.07 |
About IBRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IBRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
ImmunityBio Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
+14.17%
ImmunityBio shares are trading higher after the co...
Unlock content with
Pro Subscription
2 months ago
+0.38%
ImmunityBio shares are trading higher after the company announced it received FDA extended access authorization for the treatment of lymphopenia with ANKTIVA.
3 weeks ago · seekingalpha.com
ImmunityBio: Still Flashing Signs Of Life After Another Anktiva ApprovalRecent ASCO data and UK MHRA approval for ANKTIVA reinforce my bullish thesis, despite the FDA's Refusal to File setback. ANKTIVA's potential to reverse lymphopenia in late-stage cancer patients could...
2 months ago · seekingalpha.com
ImmunityBio: Lymphopenia Opportunity Could Provoke Short SqueezeImmunityBio, Inc.'s Anktiva shows promise for bladder cancer, but faces FDA setbacks and a rocky approval path. Peak sales for Anktiva's indications could reach $900 million by 2028, implying a 73% up...